MX345264B - Derivado de azol. - Google Patents

Derivado de azol.

Info

Publication number
MX345264B
MX345264B MX2013010570A MX2013010570A MX345264B MX 345264 B MX345264 B MX 345264B MX 2013010570 A MX2013010570 A MX 2013010570A MX 2013010570 A MX2013010570 A MX 2013010570A MX 345264 B MX345264 B MX 345264B
Authority
MX
Mexico
Prior art keywords
pharmaceutically acceptable
acceptable salts
formula
azol
derived
Prior art date
Application number
MX2013010570A
Other languages
English (en)
Other versions
MX2013010570A (es
Inventor
Yusuke Oka
Naoya Ono
Shoichi Kuroda
Yoshihisa Shirasaki
Tetsuo Takayama
Yoshinori Sekiguchi
Fumihito Ushiyama
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Publication of MX2013010570A publication Critical patent/MX2013010570A/es
Publication of MX345264B publication Critical patent/MX345264B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cosmetics (AREA)

Abstract

Se proveen compuestos novedosos que se unen a FKBP12 o sales farmacéuticamente aceptables de los mismos, así como nuevos agentes terapéuticos útiles en la prevención o tratamiento de alopecia que comprenden esos compuestos o sales farmacéuticamente aceptables de los mismos; de manera específica, se proveen compuestos representados por la fórmula (1) (Ver Formula) [en donde R1 representa ya sea la siguiente fórmula (2) o (3)] (Ver Formulas) o sales farmacéuticamente aceptables de los mismos.
MX2013010570A 2011-03-15 2012-03-15 Derivado de azol. MX345264B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011056149 2011-03-15
PCT/JP2012/056624 WO2012124750A1 (ja) 2011-03-15 2012-03-15 アゾール誘導体

Publications (2)

Publication Number Publication Date
MX2013010570A MX2013010570A (es) 2013-10-28
MX345264B true MX345264B (es) 2017-01-20

Family

ID=46830815

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013010570A MX345264B (es) 2011-03-15 2012-03-15 Derivado de azol.

Country Status (28)

Country Link
US (1) US9181229B2 (es)
EP (1) EP2687524B1 (es)
JP (1) JP5828339B2 (es)
KR (1) KR101854949B1 (es)
CN (1) CN103502240B (es)
AU (1) AU2012229834B2 (es)
BR (1) BR112013022710A2 (es)
CA (1) CA2829746C (es)
CY (1) CY1117011T1 (es)
DK (1) DK2687524T3 (es)
ES (1) ES2549559T3 (es)
HR (1) HRP20151062T1 (es)
HU (1) HUE027055T2 (es)
IL (1) IL228319A (es)
ME (1) ME02299B (es)
MX (1) MX345264B (es)
MY (1) MY162945A (es)
PH (1) PH12013501897A1 (es)
PL (1) PL2687524T3 (es)
PT (1) PT2687524E (es)
RS (1) RS54377B1 (es)
RU (1) RU2573634C2 (es)
SG (1) SG193461A1 (es)
SI (1) SI2687524T1 (es)
SM (1) SMT201500319B (es)
TW (1) TWI534142B (es)
WO (1) WO2012124750A1 (es)
ZA (1) ZA201307179B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6020396B2 (ja) * 2012-09-12 2016-11-02 大正製薬株式会社 アゾール誘導体を含有する医薬
CN107405340A (zh) * 2015-02-25 2017-11-28 大正制药株式会社 毛发生长用外用组合物
JP2017078044A (ja) * 2015-10-21 2017-04-27 大正製薬株式会社 発毛剤組成物
AU2020417293A1 (en) 2020-01-03 2022-09-01 Berg Llc Polycyclic amides as UBE2K modulators for treating cancer

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0159766B1 (ko) 1989-10-16 1998-12-01 후지사와 토모키치로 양모제 조성물
HU217621B (hu) 1991-05-09 2000-03-28 Vertex Pharmaceuticals Inc. Eljárás új glioxaloil-pipekolinsav-észterek, származékaik és az ezeket tartalmazó gyógyszerkészítmények előállítására
US5859031A (en) 1995-06-07 1999-01-12 Gpi Nil Holdings, Inc. Small molecule inhibitors of rotamase enzyme activity
US5945441A (en) 1997-06-04 1999-08-31 Gpi Nil Holdings, Inc. Pyrrolidine carboxylate hair revitalizing agents
GB9804426D0 (en) 1998-03-02 1998-04-29 Pfizer Ltd Heterocycles
AU743199B2 (en) 1998-06-02 2002-01-24 Bristol-Myers Squibb Company Neurotrophic difluoroamide agents
WO1999062880A1 (en) 1998-06-03 1999-12-09 Gpi Nil Holdings, Inc. N-linked sulfonamides of n-heterocyclic carboxylic acids or carboxylic acid isosteres
IL140042A0 (en) * 1998-06-03 2002-02-10 Guilford Pharm Inc Carboxylic acids and carboxylic acid isosteres of n-heterocyclic compounds
GB9815696D0 (en) 1998-07-20 1998-09-16 Pfizer Ltd Heterocyclics
US6228872B1 (en) 1998-11-12 2001-05-08 Bristol-Myers Squibb Company Neurotrophic diamide and carbamate agents
RU2241709C2 (ru) * 1999-07-09 2004-12-10 Орто-Макнейл Фармасьютикал, Инк. Производные азотсодержащих гетероциклических соединений и способ лечения расстройств, характеризующихся поражением нейронов
JP2001247569A (ja) 1999-08-12 2001-09-11 Japan Tobacco Inc ピロリジン誘導体又はピペリジン誘導体及びその医薬用途
US6818643B1 (en) 1999-12-08 2004-11-16 Bristol-Myers Squibb Company Neurotrophic bicyclic diamides
JP4240978B2 (ja) 2002-09-30 2009-03-18 大正製薬株式会社 アリールオキシメチルオキサジアゾール誘導体
JP4221989B2 (ja) 2002-09-30 2009-02-12 大正製薬株式会社 オキサジアゾール誘導体
CA2673841A1 (en) 2006-12-20 2008-06-26 Taisho Pharmaceutical Co., Ltd. Prophylactic or therapeutic agent for alopecia

Also Published As

Publication number Publication date
RU2573634C2 (ru) 2016-01-27
AU2012229834B2 (en) 2016-04-14
ME02299B (me) 2016-02-20
KR101854949B1 (ko) 2018-05-04
RS54377B1 (sr) 2016-04-28
BR112013022710A2 (pt) 2016-12-06
US9181229B2 (en) 2015-11-10
WO2012124750A1 (ja) 2012-09-20
EP2687524A1 (en) 2014-01-22
NZ615210A (en) 2014-12-24
MY162945A (en) 2017-07-31
JPWO2012124750A1 (ja) 2014-07-24
AU2012229834A1 (en) 2013-10-17
ES2549559T3 (es) 2015-10-29
RU2013145886A (ru) 2015-04-20
JP5828339B2 (ja) 2015-12-02
IL228319A (en) 2016-11-30
EP2687524A4 (en) 2014-08-20
EP2687524B1 (en) 2015-09-30
DK2687524T3 (en) 2015-11-09
CA2829746A1 (en) 2012-09-20
TW201249833A (en) 2012-12-16
PT2687524E (pt) 2015-12-24
HUE027055T2 (en) 2016-08-29
SG193461A1 (en) 2013-10-30
KR20140014171A (ko) 2014-02-05
CY1117011T1 (el) 2017-04-05
CN103502240A (zh) 2014-01-08
TWI534142B (zh) 2016-05-21
PL2687524T3 (pl) 2016-03-31
SMT201500319B (it) 2016-02-25
MX2013010570A (es) 2013-10-28
HRP20151062T1 (hr) 2015-11-06
US20130345419A1 (en) 2013-12-26
ZA201307179B (en) 2014-12-23
HK1189580A1 (zh) 2014-06-13
SI2687524T1 (sl) 2015-11-30
CN103502240B (zh) 2016-08-31
PH12013501897A1 (en) 2016-02-17
CA2829746C (en) 2018-10-09

Similar Documents

Publication Publication Date Title
MX2020011449A (es) Oxiesteroles y metodos de uso de los mismos.
EA201590296A1 (ru) Дейтерированный ибрутиниб
CO6480927A2 (es) Derivados de imidazolin-2-ona 1,3-disustituida como inhibidores de cyp17.
CR20140525A (es) Compuestos de N-alquiltriazol como antagonistas de LPAR
EA201492023A1 (ru) Регуляторы пути комплемента и их применение
EA201401054A1 (ru) N-циклиламиды в качестве нематоцидов
EA201492287A1 (ru) Дейтерированные производные руксолитиниба
MX361499B (es) Baricitinib deuterado.
EA201690020A1 (ru) Применение производных пиразолопиридина для лечения рака мочевого пузыря
EA201490919A1 (ru) Производные бетулина
BR112015000704A2 (pt) imidazotriazinacarbonitrilas úteis como inibidores de quinase
ECSP13012362A (es) Derivados de indolizina, su procedimiento de preparación
MX2021005052A (es) Oxiesteroles y métodos de uso de los mismos.
EA201591634A1 (ru) Дигидропиридопиримидиновые соединения
BR112014028042A2 (pt) inibidores de nampt
GB201209587D0 (en) Therapeutic compounds
EA201591024A1 (ru) Димерные соединения
EA201600619A1 (ru) Хромен и 1,1а, 2,7в-тетрагидроциклопропа[с]хромен пиридопиразиндионы в качестве модулятора гамма-секретазы
UY33907A (es) Derivados de pirazol microbicidas
PH12015501429A1 (en) Herbicidal composition
PH12015501146A1 (en) Hydantoin derivative
EA201990313A1 (ru) Производное триазолопиразинона, пригодное в качестве ингибитора фдэ1 человека
BR112013027395A2 (pt) inibidores de 17alfa-hidroxilase/c17,20-liase
CY1117011T1 (el) Παραγωγα αζολιου
UA109804C2 (xx) 2-метоксипіридин-4-ільні похідні

Legal Events

Date Code Title Description
FG Grant or registration